Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence

Sponsor
Epicentre (Other)
Overall Status
Recruiting
CT.gov ID
NCT05829772
Collaborator
Wellcome Trust (Other), Institut Pasteur (Industry), Institut National de Recherche Biomédicale. Goma, République Démocratique du Congo (Other), Ministry of Public Health, Democratic Republic of the Congo (Other), Medecins Sans Frontieres, France (Other)
7,000
2
30.4
3500
115.3

Study Details

Study Description

Brief Summary

This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol. The evidence generated from this project will be key to develop future strategies regarding cholera vaccine use in endemic settings, including places with higher burden in terms of cholera mortality

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The project will comprise three different components:

    Clinical cholera surveillance to measure cholera diseases incidence in selected African hotspots targeted by vaccination.

    Serial serological surveys to measure the prevalence of recent cholera infection (within the last 12 months).

    Identification and follow up of individuals with positive V. cholerae shedding (symptomatic or asymptomatic) among sero-survey participants and among household members of cholera confirmed cases.

    The present protocol relates to the setup of seroprevalence surveys and the follow up of individuals with positive V. cholerae shedding identified through seroprevalence surveys, in DRC.

    This protocol will allow us to assess if a large vaccination campaign reaching high coverage in cholera hotspot in Africa can allow sustained control of cholera for at least two years, by fulfilling the following specific objectives:

    1. To calculate the proportion of individuals infected with cholera recently (i.e. previous year or last 2 months) before the campaign distribution or in non-vaccinated zones (baseline survey, rural site) or following the mass OCV campaign and before the start of the usual cholera season (pre-season survey, urban site).

    2. To assess proportion of individuals recently infected (i.e. infected in the last two months or in the last year) during the expected peak-week of cholera in the area (peak survey, urban site) and at the end of the expected cholera season (post-season survey), as compared to baseline or pre-season survey.

    3. To assess the intra-household transmission and correlation in cholera recent infections among vaccinated and non-vaccinated households (post-season survey)

    4. To compare mortality linked to diarrheal diseases and potential cholera in the community of rural site before and after vaccination

    5. To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment.

    6. To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    7000 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Community-based Monitoring of Cholera Antibodies' Seroprevalence, and Home Follow-up of Positive Cases, in the Context of Cholera Vaccination Campaign, Democratic Republic of the Congo
    Actual Study Start Date :
    Sep 20, 2021
    Anticipated Primary Completion Date :
    Apr 1, 2024
    Anticipated Study Completion Date :
    Apr 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. To better characterize cholera immunization in the population of cholera hotspot in Africa and assess the impact of a large vaccination campaign reaching high coverage [2,5 years]

      Cholera-specific antibody levels will be measured in all participants for each surveys. Serial surveys will allow monitoring level of antibodies over time following the vaccination campaign

    Secondary Outcome Measures

    1. Calculate proportion of individuals infected with cholera (previous year or last 2 months) before the campaign distribution or in non-vaccinated zones or following the massOCV campaign and before the start of cholera season:pre-season survey, urban site. [2,5 years]

    2. Assess proportion of individuals infected (the last 2 months or previous year) during the expected peak-week of cholera in the area and at the end of the expected cholera season (post-season survey), as compared to baseline or pre-season survey. [2,5 years]

    3. To assess the intra-household transmission and correlation in cholera recent infections among vaccinated and non-vaccinated households (post-season survey) [2,5 years]

    4. To compare mortality linked to diarrheal diseases and potential cholera in the community of rural site before and after vaccination [2,5 years]

    5. To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment. [2,5 years]

    6. To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household. [2,5 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • All persons,
    1. Living in the randomly-selected households in targeted area AND

    2. Randomly selected among household members. Inclusions will be limited to 1 participant per household, except for one survey AND

    3. Giving his/her consent (or assent for children 13 to 17 years old) to participate in the study

    Exclusion Criteria:
    • People who decline to participate will be excluded from the study. For 2nd survey in Goma only: members of the household who cannot be reached after 2 attempts will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Epicentre/Médecins Sans Frontières Bukama Haut-Lomami Congo, The Democratic Republic of the
    2 Médecins Sans Frontières France Goma Nord Kivu Congo, The Democratic Republic of the

    Sponsors and Collaborators

    • Epicentre
    • Wellcome Trust
    • Institut Pasteur
    • Institut National de Recherche Biomédicale. Goma, République Démocratique du Congo
    • Ministry of Public Health, Democratic Republic of the Congo
    • Medecins Sans Frontieres, France

    Investigators

    • Study Director: Klaudia Porten, Epicentre
    • Study Chair: Francisco Luquero, Gavi

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Epicentre
    ClinicalTrials.gov Identifier:
    NCT05829772
    Other Study ID Numbers:
    • 2146-WT
    First Posted:
    Apr 26, 2023
    Last Update Posted:
    Apr 26, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Epicentre
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 26, 2023